Literature DB >> 23480187

Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls.

A S Bradley1, B Ford, A S Bansal.   

Abstract

Chronic fatigue syndrome (CFS) is a heterogeneous disorder of unknown aetiology characterized by disabling fatigue, headaches, sleep disturbance and several other symptoms. The onset of CFS may follow a viral infection or period of stress. Patients with CFS do not have hypogammaglobulinaemia, predisposition to recurrent bacterial infections or symptoms of autoimmunity. To date, defects in B cell numbers or function have not been shown in the literature. However, treatment with anti-B cell therapy using Rituximab has recently shown benefit to CFS patients. We therefore postulated that patients with CFS had a subtle humoral immune dysfunction, and performed extended B cell immunophenotyping. We undertook a detailed characterization of the proportions of the different B cell subsets in 33 patients with CFS fulfilling the Canadian and Fukada criteria for CFS and compared these with 24 age- and gender-matched healthy controls (HC). CFS patients had greater numbers of naive B cells as a percentage of lymphocytes: 6·3 versus 3·9% in HC (P = 0·034), greater numbers of naive B cells as a percentage of B cells: 65 versus 47% in controls (P = 0·003), greater numbers of transitional B cells: 1·8 versus 0·8% in controls (P = 0·025) and reduced numbers of plasmablasts: 0·5 versus 0·9% in controls (P = 0·013). While the cause of these changes is unclear, we speculate whether they may suggest a subtle tendency to autoimmunity.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23480187      PMCID: PMC3719933          DOI: 10.1111/cei.12043

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

Review 1.  A systematic review and critical evaluation of the immunology of chronic fatigue syndrome.

Authors:  Marc Lyall; Mark Peakman; Simon Wessely
Journal:  J Psychosom Res       Date:  2003-08       Impact factor: 3.006

2.  Chronic fatigue syndrome: a working case definition.

Authors:  G P Holmes; J E Kaplan; N M Gantz; A L Komaroff; L B Schonberger; S E Straus; J F Jones; R E Dubois; C Cunningham-Rundles; S Pahwa
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

Review 3.  Chronic fatigue syndrome, the immune system and viral infection.

Authors:  A S Bansal; A S Bradley; K N Bishop; S Kiani-Alikhan; B Ford
Journal:  Brain Behav Immun       Date:  2011-07-02       Impact factor: 7.217

4.  The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.

Authors:  K Fukuda; S E Straus; I Hickie; M C Sharpe; J G Dobbins; A Komaroff
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

5.  Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease.

Authors:  Klaus Warnatz; Axel Denz; Ruth Dräger; Moritz Braun; Christoph Groth; Guido Wolff-Vorbeck; Hermann Eibel; Michael Schlesier; Hans Hartmut Peter
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

6.  Antinuclear autoantibodies (ANA) in Gulf War-related illness and chronic fatigue syndrome (CFS) patients.

Authors:  A Skowera; E Stewart; E T Davis; A J Cleare; C Unwin; L Hull; K Ismail; G Hossain; S C Wessely; M Peakman
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

7.  Attributions and self-esteem in depression and chronic fatigue syndromes.

Authors:  R Powell; R Dolan; S Wessely
Journal:  J Psychosom Res       Date:  1990       Impact factor: 3.006

8.  Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects.

Authors:  B Piqueras; C Lavenu-Bombled; L Galicier; F Bergeron-van der Cruyssen; L Mouthon; S Chevret; P Debré; C Schmitt; E Oksenhendler
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

9.  A report--chronic fatigue syndrome: guidelines for research.

Authors:  M C Sharpe; L C Archard; J E Banatvala; L K Borysiewicz; A W Clare; A David; R H Edwards; K E Hawton; H P Lambert; R J Lane
Journal:  J R Soc Med       Date:  1991-02       Impact factor: 18.000

Review 10.  Mechanisms of B cell autoimmunity in SLE.

Authors:  Thomas Dörner; Claudia Giesecke; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2011-10-27       Impact factor: 5.156

View more
  26 in total

1.  Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.

Authors:  Matthew C Morris; Katherine E Cooney; Hooman Sedghamiz; Maria Abreu; Fanny Collado; Elizabeth G Balbin; Travis J A Craddock; Nancy G Klimas; Gordon Broderick; Mary Ann Fletcher
Journal:  Clin Ther       Date:  2019-03-28       Impact factor: 3.393

2.  Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Authors:  Andrew M Harrison; Nassir M Thalji; Alexandra J Greenberg; Carmen J Tapia; Anthony J Windebank
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

Review 3.  The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-09-26       Impact factor: 5.590

4.  Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.

Authors:  F Mensah; A Bansal; S Berkovitz; A Sharma; V Reddy; M J Leandro; G Cambridge
Journal:  Clin Exp Immunol       Date:  2016-02-22       Impact factor: 4.330

5.  Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity.

Authors:  Niloufar Khojandi; Lindsey M Kuehm; Alexander Piening; Maureen J Donlin; Eddy C Hsueh; Theresa L Schwartz; Kaitlin Farrell; John M Richart; Elizabeth Geerling; Amelia K Pinto; Sarah L George; Carolyn J Albert; David A Ford; Xiufen Chen; Justin Kline; Ryan M Teague
Journal:  Cancer Immunol Res       Date:  2020-12-10       Impact factor: 12.020

6.  B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.

Authors:  Øystein Fluge; Kristin Risa; Sigrid Lunde; Kine Alme; Ingrid Gurvin Rekeland; Dipak Sapkota; Einar Kleboe Kristoffersen; Kari Sørland; Ove Bruland; Olav Dahl; Olav Mella
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

7.  Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.

Authors:  T Nguyen; D Staines; B Nilius; P Smith; S Marshall-Gradisnik
Journal:  Biol Res       Date:  2016-05-31       Impact factor: 5.612

8.  Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.

Authors:  Sigrid Lunde; Einar K Kristoffersen; Dipak Sapkota; Kristin Risa; Olav Dahl; Ove Bruland; Olav Mella; Øystein Fluge
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

Review 9.  A Role for the Intestinal Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)?

Authors:  Navena Navaneetharaja; Verity Griffiths; Tom Wileman; Simon R Carding
Journal:  J Clin Med       Date:  2016-06-06       Impact factor: 4.241

Review 10.  The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.

Authors:  Narges Moghimi; Mario Di Napoli; José Biller; James E Siegler; Rahul Shekhar; Louise D McCullough; Michelle S Harkins; Emily Hong; Danielle A Alaouieh; Gelsomina Mansueto; Afshin A Divani
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-28       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.